Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Accretion Nutraveda IPO
Price Band
₹122.0–129.0
Issue Size
₹24.77 Cr
Lot Size
1,000 shares
Min Investment
₹258,000
2 LOTS MIN
GMP
+₹68.0 (52.71%)
Issue Price
₹129.0
Accretion Nutraveda IPO AI Summary
- Accretion Nutraveda IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹122.0–₹129.0 per share, lot size 1,000 shares (min. investment ₹258,000, 2 lots minimum).
- Subscription window: 28 Jan–30 Jan 2026, listing on 04 Feb 2026.
- Current GMP is +₹68.0 (52.71%), an estimated listing price of ₹197 — unofficial and can change daily.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Accretion Nutraveda IPO Grey Market Premium (GMP) Today
GMP
+₹68.0
GMP %
+52.71%
Est. Listing
₹197.0
Updated: 14 Jul 2026 15:52
About the Company
Accretion Nutraveda is a manufacturer of Ayurvedic and nutraceutical formulations, offering a wide range of dosage forms such as tablets, capsules, syrups, powders, oils, and topical products, including balms, creams, and gels. The company functions as a Contract Development and Manufacturing Organization (CDMO), catering to both Indian and overseas clients. Its international footprint spans markets like Sri Lanka, Singapore, and the United States. By blending traditional Ayurvedic knowledge with contemporary nutraceutical research, Accretion Nutraveda develops products targeting key wellness areas such as liver health, women’s care, bone and joint support, brain health, and respiratory well-being. Business Verticals: Domestic Sales and Merchant Exports (Loan License Model): Accounted for approximately 96.62% of total revenue in FY 2024–25. Direct Exports: Contributed around 38% of revenue, reflecting steady and ongoing growth. The company operates a manufacturing unit in Gujarat with a built-up area of nearly 10,763 square feet. The facility is fitted with advanced infrastructure, including 13 air handling units, dedicated processing zones, and robust quality assurance systems. It holds multiple certifications such as GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal, and is also licensed by FSSAI, underscoring its strong compliance and quality standards.
Company Financials (₹ Cr)
As of 2025-09-30
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
Key Ratios
EPS
₹4.91
NAV
₹14.72
ROE
81.22%
ROCE
36.98%
RoNW
48.85%
P/B Value
8.76
P/E Ratio
26.27
Market Cap
₹93.40 Cr
PAT Margin
16.33%
Debt/Equity
0.72
Promoters
Mayur Popatlal Sojitra, Ankurkumar Shantilal Patel, Paraskumar Vinubhai Parmar, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod and Vivek Ashok Kumar Patel
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Purchase of Machineries for Automation in existing Manufacturing unit 4.22 2 Purchase of Machineries for New Manufacturing Setup 8.03 3 Funding working capital requirements of the Company 5.50 4 General Corporate Purposes 3.69 5 Issue Expenses 3.33 Total 24.77
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹3.07 Cr in the year ending 31 Mar 2023, rising to ₹5.20 Cr by 31 Mar 2024, and further increasing to ₹16.06 Cr by 31 Mar 2025. However, by 30 Sep 2025, it decreased to ₹14.07 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹0.28 Cr in the year ending 31 Mar 2023, increasing to ₹0.82 Cr by 31 Mar 2024, and then to ₹2.61 Cr by 31 Mar 2025. By 30 Sep 2025, it was ₹2.33 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing gain of an IPO based on unofficial trading before the stock is listed. A higher GMP suggests strong demand for the shares, while a lower or negative GMP may indicate weak demand.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall investment strategy and risk tolerance. It's important to consider the company's fundamentals and market conditions.
Who May Want to Wait
Investors who prefer stable, established companies with predictable earnings may want to avoid IPOs like this, which can be subject to higher volatility and uncertainty in their early trading days.
IPO Timeline, Explained
The IPO process includes several key dates: the issue opens on 28 January 2026 and closes on 30 January 2026. Allotment of shares will be done on 2 February 2026, with the listing date set for 4 February 2026.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when the stock begins trading on the exchange. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and the company's performance post-IPO.
This evaluation is generated from Accretion Nutraveda's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Accretion Nutraveda IPO GMP today?
Accretion Nutraveda IPO GMP today is +₹68.0 (52.71%), indicating an estimated listing price of ₹197. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Accretion Nutraveda IPO?
The price band of Accretion Nutraveda IPO is ₹122.0–₹129.0 per share.
When does Accretion Nutraveda IPO open and close?
Accretion Nutraveda IPO opens on 28 January 2026 and closes on 30 January 2026.
When does Accretion Nutraveda IPO list on the stock exchange?
Accretion Nutraveda IPO listed on 04 February 2026 at ₹197.0.
What is the lot size for Accretion Nutraveda IPO?
The lot size for Accretion Nutraveda IPO is 1000 shares, requiring a minimum investment of ₹258,000 (2 lots).
What is the price band for the IPO?
The price band for the IPO is ₹122.0 to ₹129.0.
What is the minimum investment required?
The minimum investment required is ₹258,000.
What is the lot size for the IPO?
The lot size for the IPO is 1000 shares.
When is the listing date for the shares?
The listing date for the shares is 4 February 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing gain of an IPO based on unofficial trading.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
28 Jan 2026
Close
30 Jan 2026
Allotment
02 Feb 2026
Listing
04 Feb 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Accretion Nutraveda?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.